FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362640977> ?p ?o ?g. }

• W4362640977 endingPage "1306" @default.
• W4362640977 startingPage "1296" @default.
• W4362640977 abstract "Interventions to reduce sexually transmitted infections (STIs) among men who have sex with men (MSM) are needed. Download a PDF of the Research Summary. We conducted an open-label, randomized study involving MSM and transgender women who were taking preexposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) infection (PrEP cohort) or living with HIV infection (persons living with HIV infection [PLWH] cohort) and who had had Neisseria gonorrhoeae (gonorrhea), Chlamydia trachomatis (chlamydia), or syphilis in the past year. Participants were randomly assigned in a 2:1 ratio to take 200 mg of doxycycline within 72 hours after condomless sex (doxycycline postexposure prophylaxis) or receive standard care without doxycycline. STI testing was performed quarterly. The primary end point was the incidence of at least one STI per follow-up quarter. Of 501 participants (327 in the PrEP cohort and 174 in the PLWH cohort), 67% were White, 7% Black, 11% Asian or Pacific Islander, and 30% Hispanic or Latino. In the PrEP cohort, an STI was diagnosed in 61 of 570 quarterly visits (10.7%) in the doxycycline group and 82 of 257 quarterly visits (31.9%) in the standard-care group, for an absolute difference of −21.2 percentage points and a relative risk of 0.34 (95% confidence interval [CI], 0.24 to 0.46; P<0.001). In the PLWH cohort, an STI was diagnosed in 36 of 305 quarterly visits (11.8%) in the doxycycline group and 39 of 128 quarterly visits (30.5%) in the standard-care group, for an absolute difference of −18.7 percentage points and a relative risk of 0.38 (95% CI, 0.24 to 0.60; P<0.001). The incidences of the three evaluated STIs were lower with doxycycline than with standard care; in the PrEP cohort, the relative risks were 0.45 (95% CI, 0.32 to 0.65) for gonorrhea, 0.12 (95% CI, 0.05 to 0.25) for chlamydia, and 0.13 (95% CI, 0.03 to 0.59) for syphilis, and in the PLWH cohort, the relative risks were 0.43 (95% CI, 0.26 to 0.71), 0.26 (95% CI, 0.12 to 0.57), and 0.23 (95% CI, 0.04 to 1.29), respectively. Five grade 3 adverse events and no serious adverse events were attributed to doxycycline. Of the participants with gonorrhea culture available, tetracycline-resistant gonorrhea occurred in 5 of 13 in the doxycycline groups and 2 of 16 in the standard-care groups. The combined incidence of gonorrhea, chlamydia, and syphilis was lower by two thirds with doxycycline postexposure prophylaxis than with standard care, a finding that supports its use among MSM with recent bacterial STIs. (Funded by the National Institutes of Health; DoxyPEP ClinicalTrials.gov number, NCT03980223.) QUICK TAKE VIDEO SUMMARYDoxycycline to Prevent Bacterial STIs 02:19" @default.
• W4362640977 created "2023-04-07" @default.
• W4362640977 creator A5000176931 @default.
• W4362640977 creator A5000997859 @default.
• W4362640977 creator A5012553430 @default.
• W4362640977 creator A5013287736 @default.
• W4362640977 creator A5013536674 @default.
• W4362640977 creator A5025642389 @default.
• W4362640977 creator A5029133680 @default.
• W4362640977 creator A5040530822 @default.
• W4362640977 creator A5055595830 @default.
• W4362640977 creator A5058399472 @default.
• W4362640977 creator A5062021767 @default.
• W4362640977 creator A5065911353 @default.
• W4362640977 creator A5069281371 @default.
• W4362640977 creator A5069551580 @default.
• W4362640977 creator A5070550431 @default.
• W4362640977 creator A5085632354 @default.
• W4362640977 creator A5090773831 @default.
• W4362640977 date "2023-04-06" @default.
• W4362640977 modified "2023-10-17" @default.
• W4362640977 title "Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections" @default.
• W4362640977 cites W1664534461 @default.
• W4362640977 cites W2107367202 @default.
• W4362640977 cites W2149986546 @default.
• W4362640977 cites W2325048602 @default.
• W4362640977 cites W2500313936 @default.
• W4362640977 cites W2547050964 @default.
• W4362640977 cites W2725319213 @default.
• W4362640977 cites W2774560050 @default.
• W4362640977 cites W2791449832 @default.
• W4362640977 cites W2914873403 @default.
• W4362640977 cites W2973149394 @default.
• W4362640977 cites W3017236135 @default.
• W4362640977 cites W3142567761 @default.
• W4362640977 cites W3185444663 @default.
• W4362640977 cites W3194127984 @default.
• W4362640977 cites W4212923444 @default.
• W4362640977 cites W4225497242 @default.
• W4362640977 cites W4226358716 @default.
• W4362640977 cites W4285719527 @default.
• W4362640977 cites W4288066319 @default.
• W4362640977 doi "https://doi.org/10.1056/nejmoa2211934" @default.
• W4362640977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37018493" @default.
• W4362640977 hasPublicationYear "2023" @default.
• W4362640977 type Work @default.
• W4362640977 citedByCount "33" @default.
• W4362640977 countsByYear W43626409772023 @default.
• W4362640977 crossrefType "journal-article" @default.
• W4362640977 hasAuthorship W4362640977A5000176931 @default.
• W4362640977 hasAuthorship W4362640977A5000997859 @default.
• W4362640977 hasAuthorship W4362640977A5012553430 @default.
• W4362640977 hasAuthorship W4362640977A5013287736 @default.
• W4362640977 hasAuthorship W4362640977A5013536674 @default.
• W4362640977 hasAuthorship W4362640977A5025642389 @default.
• W4362640977 hasAuthorship W4362640977A5029133680 @default.
• W4362640977 hasAuthorship W4362640977A5040530822 @default.
• W4362640977 hasAuthorship W4362640977A5055595830 @default.
• W4362640977 hasAuthorship W4362640977A5058399472 @default.
• W4362640977 hasAuthorship W4362640977A5062021767 @default.
• W4362640977 hasAuthorship W4362640977A5065911353 @default.
• W4362640977 hasAuthorship W4362640977A5069281371 @default.
• W4362640977 hasAuthorship W4362640977A5069551580 @default.
• W4362640977 hasAuthorship W4362640977A5070550431 @default.
• W4362640977 hasAuthorship W4362640977A5085632354 @default.
• W4362640977 hasAuthorship W4362640977A5090773831 @default.
• W4362640977 hasConcept C126322002 @default.
• W4362640977 hasConcept C144024400 @default.
• W4362640977 hasConcept C149923435 @default.
• W4362640977 hasConcept C201903717 @default.
• W4362640977 hasConcept C203014093 @default.
• W4362640977 hasConcept C2776939746 @default.
• W4362640977 hasConcept C2776983459 @default.
• W4362640977 hasConcept C2777179404 @default.
• W4362640977 hasConcept C2777391075 @default.
• W4362640977 hasConcept C2778082588 @default.
• W4362640977 hasConcept C2780122209 @default.
• W4362640977 hasConcept C29456083 @default.
• W4362640977 hasConcept C3013748606 @default.
• W4362640977 hasConcept C44249647 @default.
• W4362640977 hasConcept C501593827 @default.
• W4362640977 hasConcept C71924100 @default.
• W4362640977 hasConcept C72563966 @default.
• W4362640977 hasConcept C86803240 @default.
• W4362640977 hasConcept C89423630 @default.
• W4362640977 hasConceptScore W4362640977C126322002 @default.
• W4362640977 hasConceptScore W4362640977C144024400 @default.
• W4362640977 hasConceptScore W4362640977C149923435 @default.
• W4362640977 hasConceptScore W4362640977C201903717 @default.
• W4362640977 hasConceptScore W4362640977C203014093 @default.
• W4362640977 hasConceptScore W4362640977C2776939746 @default.
• W4362640977 hasConceptScore W4362640977C2776983459 @default.
• W4362640977 hasConceptScore W4362640977C2777179404 @default.
• W4362640977 hasConceptScore W4362640977C2777391075 @default.
• W4362640977 hasConceptScore W4362640977C2778082588 @default.
• W4362640977 hasConceptScore W4362640977C2780122209 @default.
• W4362640977 hasConceptScore W4362640977C29456083 @default.
• W4362640977 hasConceptScore W4362640977C3013748606 @default.

• next